The Food and Drug Administration said it approved Merck’s (MRK) Keytruda Qlex for subcutaneous injection for adult and pediatric solid tumor indications approved for the intravenous formulation of pembrolizumab.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck receives positive EU CHMP opinion for Enflonsia
- Merck receives two positive EU CHMP opinions for Keytruda
- General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz
- Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
- Merck downgraded to Hold from Buy at Berenberg